Zhi Tong Cai Jing·2025-11-20 09:08Core Viewpoint - Fosun Pharma's subsidiary Shanghai Fuhong Hanlin Biotech has received approval for its PD-1 monoclonal antibody, Surulitinib injection, to be included in the breakthrough therapy program for gastric cancer treatment, marking a significant advancement in the field [1] Group 1: Company Developments - The drug Surulitinib, marketed as Hanshuang in China, is an innovative anti-PD-1 monoclonal antibody developed by the company [1] - The inclusion of Surulitinib in the breakthrough therapy program indicates its potential as a new treatment option for gastric cancer [1] Group 2: Industry Context - Currently, there are no approved PD-1 targeted monoclonal antibody drugs for neoadjuvant/adjuvant treatment of gastric cancer globally [1] - According to IQVIA MIDAS data, the global sales of PD-1 targeted monoclonal antibody drugs are projected to reach approximately $45.704 billion in 2024 [1]